A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus

Elizabeth R. Allen, Stefanie A. Krumm, Jayna Raghwani, Steinar Halldorsson, Angela Elliott, Victoria A. Graham, Elina Koudriakova, Karl Harlos, Daniel Wright, George M. Warimwe, Benjamin Brennan, Juha T. Huiskonen, Stuart Dowall, Richard M. Elliott, Oliver G. Pybus, Dennis R. Burton, Roger Hewson, Katie J. Doores*, Thomas A. Bowden

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

39 Citations (Scopus)

Abstract

Allen et al. reveal a molecular basis of antibody-mediated neutralization of Rift Valley fever virus, an important human and animal pathogen. They isolate and demonstrate the protective efficacy of a monoclonal antibody in a murine model of virus infection, providing a blueprint for rational therapeutic and vaccine design.

Original languageEnglish
Pages (from-to)3750-3758.e4
JournalCell Reports
Volume25
Issue number13
DOIs
Publication statusPublished - 26 Dec 2018

Bibliographical note

Publisher Copyright:
© 2018 The Author(s)

Keywords

  • Rift Valley fever virus
  • antibody
  • antiviral
  • bunyavirus
  • immune response
  • neutralization
  • phlebovirus
  • structure
  • vaccine
  • virus-host interactions

Fingerprint

Dive into the research topics of 'A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus'. Together they form a unique fingerprint.

Cite this